文献速递肿瘤 PET/CT

肛管鳞状细胞癌治疗前FDG PET-CT影像组学特征预测无进展生存

Prediction of outcome in anal squamous cell carcinoma using radiomic feature analysis of pre-treatment FDG PET-CT.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2019-09-04

本研究纳入189例接受根治性放化疗的肛管鳞状细胞癌患者,从治疗前FDG PET/CT提取影像组学特征,构建临床模型、影像组学模型及联合模型预测无进展生存。验证队列中联合模型AUC为0.7381,优于临床模型的0.6024,提示影像组学特征可能提供优于传统分期的预后信息。

要点

  • 治疗前FDG PET/CT影像组学特征可预测肛管鳞癌无进展生存
  • 联合影像组学与临床因素的模型验证队列AUC为0.7381
  • 影像组学模型验证队列AUC为0.6595,优于临床模型0.6024

核心结论

  • 治疗前FDG PET/CT提取的影像组学特征可能提供优于传统分期参数的无进展生存预后信息。
  • 需外部验证后,未来或有助于个体化放化疗方案。

研究设计与样本

  • 回顾性纳入大型三级转诊中心连续接受根治性治疗的肛管鳞状细胞癌患者,均行治疗前FDG PET/CT。
  • 共189例,训练队列145例,验证队列44例。
  • 使用LIFEx软件提取影像组学特征,采用弹性网正则化及特征选择构建逻辑回归模型,按TRIPOD指南在验证队列应用。

主要发现

  • 训练队列中分别有70.3%和68.2%的患者达到无进展生存时间点。
  • 入选预后模型的特征包括GLCM熵、NGLDM忙碌度、最小CT值、SMTV以及肿瘤和淋巴结分期。
  • 训练队列AUC:临床模型A为0.6355,影像组学模型B为0.7403,联合模型C为0.7412。
  • 验证队列AUC:临床模型A为0.6024,影像组学模型B为0.6595,联合模型C为0.7381。

临床怎么用

  • 治疗前FDG PET/CT影像组学分析或可辅助肛管鳞癌无进展生存预后分层。
  • 联合影像组学与临床因素的模型在验证队列中表现优于单纯临床模型。
  • 目前仅支持研究场景,尚需外部验证后方可用于指导个体化放化疗。

局限性

  • 研究为单中心回顾性设计,验证队列样本量较小(44例)。
  • 结论指出需外部验证后才能考虑临床用于个体化放化疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Incidence of anal squamous cell carcinoma (ASCC) is increasing, with curative chemoradiotherapy (CRT) as the primary treatment of non-metastatic disease. A significant proportion of patients have locoregional treatment failure (LRF), but distant relapse is uncommon. Accurate prognostication of progression-free survival (PFS) would help personalisation of CRT regimens. The study aim was to evaluate novel imaging pre-treatment features, to prognosticate for PFS in ASCC. METHODS: Consecutive patients with ASCC treated with curative intent at a large tertiary referral centre who underwent pre-treatment FDG-PET/CT were included. Radiomic feature extraction was performed using LIFEx software on baseline FDG-PET/CT. Outcome data (PFS) was collated from electronic patient records. Elastic net regularisation and feature selection were used for logistic regression model generation on a randomly selected training cohort and applied to a validation cohort using TRIPOD guidelines. ROC-AUC analysis was used to compare performance of a regression model encompassing standard clinical prognostic factors (age, sex, tumour and nodal stage-model A), a radiomic feature model (model B) and a combined radiomic/clinical model (model C). RESULTS: A total of 189 patients were included in the study, with 145 in the training cohort and 44 in the validation cohort. Median follow-up was 35.1 and 37. 9 months, respectively for each cohort, with 70.3% and 68.2% reaching this time-point with PFS. GLCM entropy (a measure of randomness of distribution of co-occurring pixel grey-levels), NGLDM busyness (a measure of spatial frequency of changes in intensity between nearby voxels of different grey-level), minimum CT value (lowest HU within the lesion) and SMTV (a standardized version of MTV) were selected for inclusion in the prognostic model, alongside tumour and nodal stage. AUCs for performance of model A (clinical), B (radiomic) and C (radiomic/clinical) were 0.6355, 0.7403, 0.7412 in the training cohort and 0.6024, 0.6595, 0.7381 in the validation cohort. CONCLUSION: Radiomic features extracted from pre-treatment FDG-PET/CT in patients with ASCC may provide better PFS prognosis than conventional staging parameters. With external validation, this might be useful to help personalise CRT regimens in the future.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Brown PJ, Zhong J, Frood R, et al. Prediction of outcome in anal squamous cell carcinoma using radiomic feature analysis of pre-treatment FDG PET-CT. Eur J Nucl Med Mol Imaging. 2019. PMID: 31482428. doi:10.1007/s00259-019-04495-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。